Morgan Stanley 89bio, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in 89bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,185,005 shares of ETNB stock, worth $19.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,185,005

Previous 629,229 247.25%

Holding current value

$19.8 Million

Previous $4.57 Million 369.09%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$4.83 - $10.57 $7.51 Million - $16.4 Million	1,555,776 Added 247.25%	2,185,005 $21.5 Million
Q1 2025 May 15, 2025	BUY	$6.18 - $11.66 $1.78 Million - $3.35 Million	287,278 Added 84.01%	629,229 $4.57 Million
Q4 2024 Feb 14, 2025	SELL	$7.03 - $10.05 $409,757 - $585,784	-58,287 Reduced 14.56%	341,951 $2.62 Million
Q3 2024 May 14, 2025	BUY	$7.36 - $9.66 $793,356 - $1.04 Million	107,793 Added 36.86%	400,238 $2.96 Million
Q3 2024 Nov 14, 2024	BUY	$7.36 - $9.66 $793,356 - $1.04 Million	107,793 Added 36.86%	400,238 $2.96 Million
Q2 2024 May 14, 2025	SELL	$7.31 - $10.9 $361,888 - $539,615	-49,506 Reduced 14.48%	292,445 $2.34 Million
Q2 2024 Oct 17, 2024	SELL	$7.31 - $10.9 $3.8 Million - $5.67 Million	-520,177 Reduced 64.01%	292,445 $2.34 Million
Q2 2024 Aug 14, 2024	SELL	$7.31 - $10.9 $3.8 Million - $5.67 Million	-520,177 Reduced 64.01%	292,445 $2.34 Million
Q1 2024 Oct 17, 2024	BUY	$8.13 - $13.77 $4.23 Million - $7.16 Million	520,177 Added 177.87%	812,622 $9.46 Million
Q1 2024 Aug 16, 2024	SELL	$8.13 - $13.77 $5.5 Million - $9.32 Million	-676,638 Reduced 45.43%	812,622 $9.46 Million
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $5.5 Million - $9.32 Million	-676,638 Reduced 45.43%	812,622 $9.46 Million
Q4 2023 Aug 16, 2024	BUY	$6.66 - $16.03 $7.97 Million - $19.2 Million	1,196,815 Added 409.24%	1,489,260 $16.6 Million
Q4 2023 Feb 13, 2024	BUY	$6.66 - $16.03 $5.92 Million - $14.3 Million	889,506 Added 148.31%	1,489,260 $16.6 Million
Q3 2023 Nov 15, 2023	SELL	$15.06 - $19.41 $15.8 Million - $20.3 Million	-1,047,262 Reduced 63.59%	599,754 $9.26 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $483,604 - $752,919	34,177 Added 2.12%	1,647,016 $31.2 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $15.8 Million - $25.5 Million	1,507,728 Added 1434.42%	1,612,839 $24.6 Million
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $150,442 - $346,943	-27,254 Reduced 20.59%	105,111 $1.34 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $102,698 - $238,042	34,006 Added 34.57%	132,365 $767,000
Q2 2022 Oct 27, 2022	BUY	$2.09 - $4.02 $58,624 - $112,760	28,050 Added 39.9%	98,359 $317,000
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $58,624 - $112,760	28,050 Added 39.9%	98,359 $317,000
Q1 2022 Oct 27, 2022	SELL	$3.45 - $14.99 $96,772 - $420,469	-28,050 Reduced 28.52%	70,309 $264,000
Q1 2022 May 13, 2022	BUY	$3.45 - $14.99 $108,167 - $469,981	31,353 Added 80.48%	70,309 $264,000
Q4 2021 Feb 14, 2022	SELL	$11.15 - $19.66 $1.96 Million - $3.45 Million	-175,428 Reduced 81.83%	38,956 $509,000
Q3 2021 Nov 15, 2021	BUY	$14.91 - $21.31 $3.2 Million - $4.57 Million	214,384 New	214,384 $4.2 Million

Others Institutions Holding ETNB

# of Institutions

212

Shares Held

162M

Call Options Held

289K

Put Options Held

1.6M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $420M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account